Areas covered: Available data on epidemiology, type, and possible risk factors for nephrotoxicity of sofosbuvir-containing treatment are reviewed. Related articles were collected by searching Scopus, Pubmed, and Science direct.
The FDA has approved supplemental application for Harvoni (ledipasvir and sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV)...
Areas covered: This is a review of the preclinical and clinical development of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), an interferon-free, oral, once daily, pangenotypic treatment for chronic HCV infection.
The FDA has approved supplemental applications for Sovaldi (sofosbuvir), from Gilead Sciences, to treat hepatitis C virus (HCV) in children...
Background: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.
Nucleotide compounds like sofosbuvir, acyclovir, and tenofovir have proven to be amongst the most potent orally available antiviral treatments. These...
Gilead Sciences, Inc. has announced results from a Phase III study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for...
Bristol-Myers Squibb Company (BMS) announced that Daklinza (daclatasvir), an NS5A replication complex inhibitor, has been approved on 24 July 2015...
Gilead Sciences announced that the European Commission has granted marketing authorization for Vosevi (sofosbuvir 400mg/velpatasvir 100mg/voxilaprevir 100mg), as a once-daily...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Epclusa (sofosbuvir + velpatasvir), from Gilead Sciences in chronic hepatitis C virus (HCV) infection.